Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat.

Ji XH, Ji JZ, Zhang H, Li BM.

Neuropsychopharmacology. 2008 Aug;33(9):2263-71. Epub 2007 Oct 24.

2.

Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats.

Marrs W, Kuperman J, Avedian T, Roth RH, Jentsch JD.

Neuropsychopharmacology. 2005 Aug;30(8):1500-10.

3.

Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition.

Klamer D, PĂ„lsson E, Fejgin K, Zhang J, Engel JA, Svensson L.

Psychopharmacology (Berl). 2005 May;179(2):479-88. Epub 2004 Dec 24.

PMID:
15619121
4.

Alpha-2 agonist-induced memory impairment is mediated by the alpha-2A-adrenoceptor subtype.

Galeotti N, Bartolini A, Ghelardini C.

Behav Brain Res. 2004 Aug 31;153(2):409-17.

PMID:
15265636
5.
6.

Psychotomimetic effects of drugs--a common pathway to schizophrenia?

Gerber DJ, Tonegawa S.

N Engl J Med. 2004 Mar 4;350(10):1047-8. No abstract available.

PMID:
14999118
7.
8.

Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.

Lorrain DS, Schaffhauser H, Campbell UC, Baccei CS, Correa LD, Rowe B, Rodriguez DE, Anderson JJ, Varney MA, Pinkerton AB, Vernier JM, Bristow LJ.

Neuropsychopharmacology. 2003 Sep;28(9):1622-32. Epub 2003 Jun 25.

9.

Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia.

Krystal JH, Anand A, Moghaddam B.

Arch Gen Psychiatry. 2002 Jul;59(7):663-4. No abstract available.

PMID:
12090822
10.

Glutamatergic mechanisms in schizophrenia.

Tsai G, Coyle JT.

Annu Rev Pharmacol Toxicol. 2002;42:165-79. Review.

PMID:
11807169
11.

Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex.

Devoto P, Flore G, Pani L, Gessa GL.

Mol Psychiatry. 2001 Nov;6(6):657-64.

12.

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.

Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR.

Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54. Review.

PMID:
11549216
13.

The release of noradrenaline in the locus coeruleus and prefrontal cortex studied with dual-probe microdialysis.

Pudovkina OL, Kawahara Y, de Vries J, Westerink BH.

Brain Res. 2001 Jul 6;906(1-2):38-45.

PMID:
11430860
14.

Modulation of MK-801-induced behaviour by noradrenergic agents in mice.

Harkin A, Morris K, Kelly JP, O'Donnell JM, Leonard BE.

Psychopharmacology (Berl). 2001 Mar 1;154(2):177-88.

PMID:
11314680
15.

Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats.

Birnbaum SG, Podell DM, Arnsten AF.

Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.

PMID:
11164065
16.
17.

Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors.

Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS.

J Neurosci. 2000 May 1;20(9):3504-11.

18.

Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats.

Kubota T, Hirota K, Yoshida H, Takahashi S, Anzawa N, Ohkawa H, Kushikata T, Matsuki A.

Psychopharmacology (Berl). 1999 Oct;146(3):335-8.

PMID:
10541735
19.
20.

Supplemental Content

Support Center